Published online before print July 8, 2002, doi: 10.1161/01.CIR.0000023043.02648.51
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2002;106:466.)
© 2002 American Heart Association, Inc.
Clinical Investigation and Reports |
Insulin-Dependent Activation of Endothelial Nitric Oxide Synthase Is Impaired by O-Linked Glycosylation Modification of Signaling Proteins in Human Coronary Endothelial Cells
From Department of Internal Medicine (M.F., R.M., F.F., D.L., P.S., R.L.) and Department of Biopathology (A.M., L.G.S.), University of Tor Vergata, Rome, Italy; Department of Medicine (M.L.H.), College of Physicians and Surgeons of Columbia University, New York, NY; and Department of Clinical and Experimental Medicine (G.S.), University of Catanzaro, Catanzaro, Italy.
Correspondence to Massimo Federici, Department of Internal Medicine, University of Rome "Tor Vergata," Via Montpellier 1, 135, 00133 Rome, Italy. E-mail federicm{at}uniroma2.it
 |
Abstract |
|---|
 Top Abstract IntroductionMethodsResultsDiscussionReferences |
|---|
Background— Hyperglycemia impairs functional properties of cytosolic and nuclear proteins via O-linked glycosylation modification (O-GlcNAcylation). We studied the effects of O-GlcNAcylation on insulin signaling in human coronary artery endothelial cells.
Methods and Results— O-GlcNAcylation impaired the metabolic branch of insulin signaling, ie, insulin receptor (IR) activation of the IR substrate (IRS)/phosphatidylinositol 3-kinase (PI3-K)/Akt, whereas it enhanced the mitogenic branch, ie, ERK-1/2 and p38 (mitogen-activated protein kinase). Both in vivo and in vitro phosphorylation of endothelial nitric oxide synthase (eNOS) by Akt were reduced by hyperglycemia and hexosamine activation. Insulin-induced eNOS activity in vivo was reduced by hyperglycemia and hexosamine activation, which was coupled to increased activation and expression of matrix metalloproteinase-2 and -9; these phenomena were reversed by inhibition of the hexosamine pathway. Finally, carotid plaques from type 2 diabetic patients showed increased endothelial O-GlcNAcylation with respect to nondiabetics.
Conclusions— Our data show that hyperglycemia, through the hexosamine pathway, impairs activation of the IR/IRS/PI3-K/Akt pathway, resulting in deregulation of eNOS activity.
Key Words: atherosclerosis • diabetes mellitus • endothelium • insulin • metalloproteinases
|
Introduction |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Endothelial dysfunction is an early step in the pathogenesis of atherosclerosis and is a feature of insulin-resistant states such as diabetes, obesity, and hypertension.1–3 Insulin induces vasodilation by modulating endothelial nitric oxide synthase (eNOS) activity and expression through activation of the insulin receptor (IR)/IR substrate (IRS)-1 and IRS-2/phosphatidylinositol 3-kinase (PI3-K)/protein kinase B/Akt signaling cascade.4–7 In type 2 diabetes, insulin resistance is associated with impaired activation of the IR/IRS/PI3-K pathway but normal activation of the Ras/mitogen-activated protein kinase (MAPK) pathway.8–10
Activation of the hexosamine pathway by hyperglycemia results in O-linked glycosylation modification (O-GlcNAcylation) of Ser/Thr residues of insulin-signaling proteins, which affects receptor assembly and PI3-K activation.11–13 It was recently observed that hyperglycemia has toxic effects on endothelial cells through induction of mitochondrial superoxide.14,15 Superoxide was found to shift glucose metabolism through the hexosamine pathway, and increased glucosamine production was proposed to contribute to endothelial cell deregulation.14,15 Endothelial production of NO plays an important role in preventing vascular disease through regulation of thrombosis, inflammation, vascular tone, and remodeling.1 NO has been shown to inhibit smooth muscle cell migration and proliferation, as well as synthesis and secretion of extracellular matrix proteins.1,16 A key role in this process is played by matrix metalloproteinases (MMPs), which degrade extracellular matrix proteins and are counterbalanced by tissue inhibitors of metalloproteinases (TIMPs).1,16 An altered balance between MMPs and TIMPs has been implicated in many conditions related to atherosclerosis, such as plaque instability and restenosis after angioplasty, observed in diabetic patients.16,17 These observations prompted us to test the hypothesis that hyperglycemia via hexosamine activation induces selective insulin resistance in human coronary artery endothelial cells (HCAECs) by affecting key insulin-signaling molecules.
|
Methods |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Materials
Antibodies and reagents used were as follows: anti-phosphotyrosine, anti-IRß, anti-IGF-1Rß, anti-IRS-1, anti-IRS-2, anti-p85, anti-ser1177-eNOS, and plasmid pc-DNA3 encoding constitutively active Akt (UBI, Upstate, Lake Placid, NY); anti-Akt, anti-Ser473-Akt, anti-Ser259-c-Raf-1, anti-c-Raf-1, anti-ERK-1/2, and anti-phospho-ERK-1/2 (Cell Signaling Technology, Waltham, Mass); anti-human eNOS (Transduction Laboratories, Franklin Lakes, NJ); anti-O-linked glycosylation RL-2 (Affinity Bioreagents, Golden, Colo); anti-MMP-2, anti-MMP-9, and PD098059 (Calbiochem, San Diego, Calif); and anti-TIMP-1, anti-TIMP-2, and anti-TIMP-3 (Chemicon, Temecula, Calif). All other chemicals were from Sigma (St Louis, Mo).
Cell Culture
HCAECs were grown according to the manufacturer’s instructions (Clonetics Corp, Brescia, Italy). Dose-response experiments were performed at different glucose (5.5, 10, 20, and 30 mmol/L) and glucosamine (0, 1.5, 7.5, and 15 mmol/L)18,19 concentrations for 72 hours to compare O-GlcNAcylation of immunoprecipitated IRSs and p85. Intracellular ATP levels were measured by an ATP assay kit (Calbiochem) as indicated by the manufacturer. HCAECs from passages 3 to 6 were cultured for 72 hours in the presence of 5.5 mmol/L glucose, 20 mmol/L glucose (high glucose; HG), 7.5 mmol/L glucosamine (GLN), and 5.5 mmol/L glucose plus 14.5 mmol/L mannitol. Azaserine (10 µmol/L) and PD098059 (100 µmol/L) were used to block the hexosamine pathway in 20 mmol/L glucose (HG plus azaserine) or MAPK activity (HG plus PD098059).
IRS-1, IRS-2, Akt, ERK-1/2, p38, and c-Raf-1 Phosphorylation and Anti-Phosphotyrosine–Associated PI3-K Activity
At the end of treatments, HCAECs were serum starved for 16 hours and incubated in the presence or absence of 50 nmol/L insulin for 10 minutes. Cells lysis, immunoprecipitations, Western blotting, and PI3-K assays were performed as described previously.20 Membranes blotted with anti-phosphotyrosine or phosphoactive antibodies were stripped and reprobed with primary antibodies to verify expression levels. Protein phosphorylation levels were normalized to the matching densitometric values of nonphosphorylated proteins. Autoradiographs were quantified with a FluorImager (Bio-Rad).
In Vitro Akt Kinase Assay on Immunoprecipitated eNOS
eNOS immunoprecipitates were obtained from cells cultured as described above. Active Akt kinase was obtained by immunoprecipitation of overexpressed Myc-tagged constitutively active Akt from transfected HEK293.21,22 The immunoprecipitates were combined and incubated in Akt kinase assay buffer, and the reaction was terminated as described previously.20–22 Then, samples were subjected to 8% SDS-PAGE and analyzed by a phosphorimager (Bio-Rad). eNOS content, phosphorylation on Ser1177, and O-GlcNAcylation were verified by Western blotting with specific antibodies.
eNOS Activity
The amount of NOS activity produced by HCAECs was measured by the NOS Detect assay kit (Stratagene) through the conversion of [3H]L-arginine to [3H]L-citrulline, according to the manufacturer’s instructions.6 Data were normalized by the amount of protein and reaction time.
SDS-PAGE Zymography and Reverse Zymography
MMP activity could be quantitatively estimated by a zymography assay as described previously.23 In this method, proteins that had gelatinolytic activity were detected on electrophoretic migration on the basis of their capacity to digest the gelatin substrate incorporated into gels. To this end, cultured supernatants were concentrated, mixed with an equal volume of nonreducing buffer, and electrophoresed in discontinuous 10% SDS-PAGE gel containing 1 mg/mL gelatin (Novex). Gels were incubated in Novex zymogram renaturing buffer and equilibrated in Novex zymogram developing buffer for 18 hours at 37°C. Gels were stained with Coomassie blue R-250 followed by destaining in 5% methanol and 7% acetic acid. MMPs appear as white bands on a blue background. Reverse zymography was performed to measure TIMP activity as follows: samples were electrophoresed in discontinuous 12% SDS-PAGE gels containing 1 mg/mL gelatin and conditioned medium from baby hamster kidney (BHK) cells expressing gelatinase A. The gels were washed and incubated for 24 hours at 37°C in regenerating buffer (50 mmol/L Tris/HCl, pH7.5, and 5 mmol/L CaCl2). Under these conditions, TIMPs inhibit gelatin digestion by activated MMPs, producing dark blue bands against a lighter background. Density of bands was quantified by the National Institutes of Health IMAGE program, version 1.6. A single value was derived for MMP-9 and for MMP-2 by adding the bands associated with both pro and activated forms.
Tissue Immunohistochemistry
Formaldehyde-fixed and paraffin-embedded carotid and ovary sections were immunostained as described previously24 with RL2 antibody according to the manufacturer’s instructions. Negative controls were performed that omitted the primary antibody. Positive signals in the cap plaque were measured by the National Institutes of Health IMAGE program, version 1.6.
Statistical Analysis
Results are reported as percent increase with respect to control. Statistical analyses were performed with 1-way ANOVA or Student’s t test as indicated. Values of P<0.05 were considered statistically significant.
|
Results |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Dose-Dependent Effects of Glucose and Glucosamine on HCAECs
O-GlcNAcylation levels of IRSs and p85 proteins were assessed on exposure to different glucose and glucosamine concentrations. Results showed that IRS-1, IRS-2, and p85 O-GlcNAcylation levels were increased by 400%, 175%, and 170%, respectively, at 10 mmol/L glucose or 1.5 mmol/L glucosamine and by 600%, 210%, and 200%, respectively, at 20 mmol/L glucose or 7.5 mmol/L glucosamine. No further increase in IRS and p85 protein O-GlcNAcylation was observed by increasing concentrations up to 30 mmol/L glucose or 15 mmol/L glucosamine (Figure 1). Intracellular ATP levels were similar in cells cultured under the different conditions with respect to control cells (data not shown). Subsequent experiments were thus performed that studied cells cultured in glucose 5.5 mmol/L (control) versus HG or GLN. A similar glucosamine concentration was used in human cells and porcine mesangioblasts to mimic the chronic hyperglycemia-induced hyperactivity of the hexosamine pathway that is characteristic of type 2 diabetes.11,18,19
|
HG and GLN Impair Insulin Signaling in HCAECs
Incubation of HCAECs with HG and GLN resulted in 50% reduction in insulin-stimulated IR tyrosine phosphorylation with respect to control cells (P<0.001; n=3;.Figure 2a). No insulin-induced IGF-1R-ß (insulin-like growth factor-1 receptor-ß) phosphorylation was observed in these conditions (data not shown). Insulin-induced tyrosine phosphorylation of IRS-1 was reduced by 56% and 63% in HG and GLN, respectively (P<0.0001; n=3). Insulin-stimulated coprecipitation of p85 with IRS-1 was reduced by 20% and 35% in HG and GLN, respectively (P<0.001; n=3). Insulin-stimulated IRS-1–associated PI3-K activity was reduced by 55% and 45% in HG and GLN, respectively (P<0.001; n=3; Figure 2b). Similarly, insulin-induced IRS-2 tyrosine phosphorylation, p85 coprecipitation with IRS-2, and IRS-2–associated PI3-K activity were significantly reduced in HG and GLN HCAECs with respect to control HCAECs (Figure 2c). No differences were observed in IR, IRS-1, IRS-2 (Figure 2), or p85 (data not shown) levels under basal or activated conditions. PI3-K activity associated with phosphotyrosine immunoprecipitates was reduced by 50% and 28% in HG and GLN HCAECs, respectively (P<0.001; n=3; Figure 3a). Insulin-stimulated Akt phosphorylation was reduced by 30% and 28% in HG and GLN HCAECs, respectively (P<0.0005; n=4). Insulin-stimulated c-Raf-1 phosphorylation was reduced by 61% and 47% in HG and GLN HCAECs, respectively (P<0.0004; n=3). Insulin-induced ERK-1/2 phosphorylation was increased by 49% and 53% in HG and GLN HCAECs, respectively (P<0.0001; n=3). Insulin-stimulated p38 phosphorylation was increased by 275% and 118% in HG and GLN HCAECs, respectively (P<0.0001; n=3; Figure 3, b through e). No differences were observed in Akt, c-RAF-1, ERK-1/2, and p38 total protein levels under basal or activated conditions (Figure 3, b through e). No differences in insulin-stimulated signaling pathways were observed in control and mannitol conditions (data not shown).
|
|
P<0.0005, P<0.0004, by ANOVA. PY and py indicate phosphotyrosine; tyr, tyrosine; phospho, phosphorylation; and IP, ImmunoPrecipitation.
eNOS Phosphorylation Is Reduced by HG and GLN
Analysis of eNOS protein by the YinOYang prediction server25 allowed identification of several O-GlcNAcylation sites around the Ser1177 residue (Figure 4a). eNOS O-GlcNAcylation was increased by 294% in HG HCAECs, whereas inhibition of hexosamine biosynthesis by the glutamine:fructose-6-phosphate aminotransferase (GFAT) inhibitor azaserine reversed the HG effect (P<0.0001; n=4; Figure 4b). In the in vitro kinase assay, 32P incorporation into eNOS induced by constitutively active Akt was reduced by 46% and 83% in eNOS immunoprecipitated from HG and GLN HCAECs, respectively (P<0.0001; n=4) and was reversed by azaserine treatment (Figure 4c). Immunoblotting with anti-pSer1177eNOS reproduced results observed with kinase assays (data not shown and Figure 4c). There was an inverse relation between O-GlcNAcylation extent and phosphorylation status (Figure 4c). Insulin-stimulated pSer1177eNOS phosphorylation was reduced by 37% and 42% in HG and GLN HCAECs, respectively (P<0.012; n=4; Figure 4d). Insulin-stimulated eNOS activity was reduced by 27% and 22% in HG and GLN HCAECs, respectively (P<0.001; n=4); no differences were observed in basal eNOS activity (Figure 4e).
|
MMP-2 and MMP-9 Activity Is Increased in HCAECs Treated by HG and GLN
NO produced by eNOS inhibits MMP-2 and MMP-9 activity 1.16,26 MMP-9 activity was increased by 64% and 72% in HG and GLN HCAECs, respectively (P<0.01; n=3). MMP-2 activity was increased by 87% and 119% in HG and GLN HCAECs, respectively (P<0.01). Azaserine completely reversed the effects of HG and GLN on both pro-MMP-2 and pro-MMP-9 (P<0.001 for both MMP-9 and MMP-2; Figure 5, a and b). MMP-9 and MMP-2 expression was markedly increased in both HG and GLN HCAECs (P<0.001; Figure 5b). To verify whether increased ERK-1/2 activity observed in HG and GLN HCAECs contributed to enhanced MMP-9 and MMP-2 expression, we incubated cells with PD098059 inhibitor. Inhibition of ERK-1/2 did not significantly reduce the HG- and GLN-dependent increase in activity of MMP-9 and MMP-2 (Figure 5a) and protein levels (data not shown).
|
TIMP-3 Levels Are Reduced in HCAECs Incubated With HG and GLN
TIMPs inhibit activation of pro-MMP to active MMP. Reverse zymography assay of HCAEC culture media revealed no defects in TIMP-1 and TIMP-2 expression (Figure 5c and data not shown). By contrast, TIMP-3 activity was reduced by 88% and 85% in HG and GLN HCAECs, respectively (P<0.001; n=3); TIMP-3 protein expression was reduced by 74% and 84% in HG and GLN HCAECs, respectively (P<0.013; n=3; Figure 5c).
GlcNAcylation Is Increased in Atherosclerotic Plaque of Diabetic Patients
We next assessed O-GlcNAcylation of endothelial cells in vivo by immunostaining with RL2 antibody of carotid plaques from nondiabetic and diabetic subjects. O-GlcNAcylation immunoreactivity was barely detectable in control endothelial cells from nonatherosclerotic small vessels (Figure 6, a through f; Table). The endothelial layer of carotid plaques showed intense signal in both cytoplasm and nuclear compartments of diabetic patients arteries compared with nondiabetic subjects (Figure 6, g and h). No immunoreactivity was detected when the primary antibody was omitted (data not shown). O-GlcNAcylation immunoreactivity in the cap plaque was 6.6-fold increased in diabetic samples (P<0.0016; n=4 Figure 6i).
|
|
|
Discussion |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Activation of the hexosamine pathway has been proposed as a link between glucose toxicity and development of diabetic complications, 9–15 whereas hyperinsulinemia, secondary to insulin resistance, has been hypothesized to promote the atherogenic effects of insulin.27–29 In the present report, we show that activation of the hexosamine biosynthesis in HCAECs determines epistatic defects in the pathway that transduces the insulin effect from the membrane receptor to eNOS activation, by increased O-GlcNAcylation of key signaling molecules. Reduction of eNOS activity is associated with increased expression of MMP-2 and MMP-9 and decreased expression of TIMP-3, which might contribute to the development of macrovascular disease.1,16 Increased O-GlcNAcylation of signaling molecules in the PI3-K pathway could also explain increased MAPK activity, because Akt is known to negatively regulate the upstream MAPK activator Raf-1.30,31 Thus, O-GlcNAcylation impairment of the metabolic IR/IRS/PI3-K/Akt pathway might impair the protective effects of eNOS and also might promote vascular cell growth and endothelin-1 and plasminogen activator inhibitor-1 overexpression by MAPK hyperactivation.15,27–29
There is evidence that activation of Akt may exert antiatherogenic effects by phosphorylating eNOS on Ser1177.21,22 Prediction of eNOS O-GlcNAcylation sites allowed us to identify several potential sites surrounding Ser1177 but not other phosphorylation sites, such as Thr495 and Ser116 (Figure 3a).25 We found that treatment of HCAECs with HG and GLN caused a marked reduction in insulin-induced eNOS activity as a result of increased O-GlcNAcylation of key insulin-signaling elements. Interestingly, blockade of the hexosamine pathway activation by azaserine reversed the effect of HG on O-GlcNAcylation levels, insulin-induced activity, and Ser1177 phosphorylation of eNOS. It is conceivable that O-GlcNAcylation of Ser1177 or close residues prevents Akt from phosphorylating and activating eNOS. However, because azaserine is a nonspecific inhibitor of GFAT, the rate-limiting enzyme in hexosamine metabolism, the present data suggest but do not conclusively document causality. While this article was in preparation, Du et al32 demonstrated that inhibition of GFAT through antisense diminished HG-dependent O-GlcNAcylation of eNOS. Thus, they provided causal evidence that O-GlcNAcylation of eNOS induced by hyperglycemia impaired basal enzyme activity. Moreover, they observed that mutation of the Akt site Ser1177 resulted in reduction of eNOS O-GlcNAcylation in bovine endothelial cells exposed to high glucose levels. Our data are in agreement with the observation by Du et al32 and provide new evidence that O-GlcNAcylation could play a role in modulating the dynamics of insulin signaling in the vasculature.
eNOS has been shown to inhibit both MMP-2 and MMP-9 activity through NO production.16,25 Interestingly, in muscle and aorta from IR+/- insulin-resistant diabetic mice, we have observed decreased expression and activity of TIMP-3, accompanied by increased MMP-2 and MMP-9 activity (M.F. and D. Accili, MD, unpublished data, 2001). Likewise, in HCAECs, impairment of insulin signaling involving the PI3-K/Akt/eNOS pathway induced by HG or GLN is associated with increased MMP-2 and MMP-9 expression and activity and reduced TIMP-3. By contrast, inhibition of MAPK activity by a selective inhibitor did not modify increased MMP activity observed in this system. To verify whether O-GlcNAcylation is present in the vasculature of diabetic patients, nonatherosclerotic vessels and carotid plaques from both type 2 diabetic and nondiabetic subjects were analyzed. Weak O-GlcNAcylation was observed in endothelium of nonatherosclerotic arteries. By contrast, carotid plaques from diabetic patients revealed a marked increase of O-GlcNAcylation in both cytoplasm and nuclear compartments of endothelial cells compared with nondiabetic subjects. The presence of O-GlcNAcylation in carotid plaques from nondiabetic subjects, although at lower levels, is of interest because it could be speculated to be related to superoxide overproduction by factors other than hyperglycemia. Superoxide production is known to favor hexosamine pathway activation, and there is evidence that inhibition of mitochondrial superoxide generated by HG reduces hexosamine pathway activation and eNOS O-GlcNAcylation.15,32
Glucosamine has been shown recently to suppress inducible NO synthase protein and activity in macrophages activated by inflammatory cytokines.33 This observation could explain the positive effect of glucosamine in the treatment of arthritis.33 Although we did not assess the effect of glucosamine on inducible NO synthase in our cell system, there is evidence that glucose toxicity adversely affects diabetic macrovascular complications,34 and acute infusion of glucosamine in humans reproduces some metabolic features of diabetes.35
In conclusion, our study data support the idea that hyperglycemia, acting at least in part through the hexosamine pathway, may contribute to the development of diabetic macrovascular complications by selectively impairing the metabolic branch of insulin signaling that involves the PI3-K/Akt/eNOS pathway.
|
Acknowledgments |
|---|
This work was supported by the following grants: Ministry of Health grant RS2000 ICS 030.6/RF00-49 (Dr Federici), Ministry of Health grant RS99 ICS 120.4/RF99.11 and Ministry of University grant PRIN-COFIN MURST 1999 (Dr Lauro); and CEE QLG1-CT-1999-00674, Italian National Research Council grant CNR 99.02597.CT04, and Società Italiana di Diabetologia grant SID-ONLUS 1998 (Dr Sesti).
Received March 5, 2002; revision received May 8, 2002; accepted May 9, 2002.
|
References |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
1. Lusis AJ. Atherosclerosis. Nature. 2000; 407: 233–241.[CrossRef][Medline] [Order article via Infotrieve]
2. Steinberg HO, Chaker H, Leaming R, et al. Obesity/insulin resistance is associated with endothelial dysfunction: implications for the syndrome of insulin resistance. J Clin Invest. 1996; 97: 2601–2610.[Medline] [Order article via Infotrieve]
3. Balletshofer BM, Rittig K, Enderle MD, et al. Endothelial dysfunction is detectable in young normotensive first-degree relatives of subjects with type 2 diabetes in association with insulin resistance. Circulation. 2000; 101: 1780–1784.
4. Zeng G, Nystrom FH, Ravichandran LV, et al. Roles for insulin receptor, PI3-kinase, and Akt in insulin-signaling pathways related to production of nitric oxide in human vascular endothelial cells. Circulation. 2000; 101: 1539–1545.
5. Kuboki K, Jiang ZY, Takahara N, et al. Regulation of endothelial constitutive nitric oxide synthase gene expression in endothelial cells and in vivo: a specific vascular action of insulin. Circulation. 2000; 101: 676–681.
6. Aljada A, Saadeh R, Assian E, et al. Insulin inhibits the expression of intercellular adhesion molecule-1 by human aortic endothelial cells through stimulation of nitric oxide. J Clin Endocrinol Metab. 2000; 85: 2572–2575.
7. Montagnani M, Chen H, Barr VA, et al. Insulin-stimulated activation of eNOS is independent of Ca2+ but requires phosphorylation by Akt at Ser(1179). J Biol Chem. 2001; 276: 30392–30398.
8. Cusi K, Maezono K, Osman A, et al. Insulin resistance differentially affects the PI3-kinase- and MAP kinase-mediated signaling in human muscle. J Clin Invest. 2000; 105: 311–320.[Medline] [Order article via Infotrieve]
9. Virkamaki A, Ueki K, Kahn CR. Protein-protein interaction in insulin signaling and the molecular mechanisms of insulin resistance. J Clin Invest. 1999; 103: 931–943.[Medline] [Order article via Infotrieve]
10. Sesti G, Federici M, Hribal ML, et al. Defects of the insulin receptor substrate (IRS) system in human metabolic disorders. FASEB J. 2001; 15: 2099–2111.
11. Wells L, Vosseller K, Hart GW. Glycosylation of nucleocytoplasmic proteins: signal transduction and O-GlcNAc. Science. 2001; 291: 2376–2378.
12. Federici M, Giaccari A, Hribal ML, et al. Evidence for glucose/hexosamine in vivo regulation of insulin/IGF-I hybrid receptor assembly. Diabetes. 1999; 48: 2277–2285.[Abstract]
13. Patti ME, Virkamaki A, Landaker EJ, et al. Activation of the hexosamine pathway by glucosamine in vivo induces insulin resistance of early postreceptor insulin signaling events in skeletal muscle. Diabetes. 1999; 48: 1562–1571.[Abstract]
14. Nishikawa T, Edelstein D, Du XL, et al. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature. 2000; 404: 787–790.[CrossRef][Medline] [Order article via Infotrieve]
15. Du XL, Edelstein D, Rossetti L, et al. Hyperglycemia-induced mitochondrial superoxide overproduction activates the hexosamine pathway and induces plasminogen activator inhibitor-1 expression by increasing Sp1 glycosylation. Proc Natl Acad Sci U S A. 2000; 97: 12222–12226.
16. Galis ZS, Khatri JJ. Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ Res. 2002; 90: 251–262.
17. Burton SE. Acceleration of restenosis by diabetes: pathogenetic implications. Circulation. 2001; 103: 1185–1187.
18. Ciaraldi TP, Carter L, Nikoulina S, et al. Glucosamine regulation of glucose metabolism in cultured human skeletal muscle cells: divergent effects on glucose transport/phosphorylation and glycogen synthase in non-diabetic and type 2 diabetic subjects. Endocrinology. 1999; 140: 3971–3980.
19. Kolm-Litty V, Sauer U, Nerlich A, et al. High glucose-induced transforming growth factor beta1 production is mediated by the hexosamine pathway in porcine glomerular mesangial cells. J Clin Invest. 1998; 101: 160–169.[Medline] [Order article via Infotrieve]
20. Federici M, Hribal ML, Ranalli M, et al. The common Arg972 polymorphism in insulin receptor substrate-1 causes apoptosis of human pancreatic islets. FASEB J. 2001; 15: 22–24.
21. Fulton D, Gratton JP, McCabe TJ, et al. Regulation of endothelium-derived nitric oxide production by the protein kinase Akt. Nature. 1999; 399: 597–601.[CrossRef][Medline] [Order article via Infotrieve]
22. Dimmeler S, Fleming I, Fisslthaler B, et al. Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature. 1999; 399: 601–605.[CrossRef][Medline] [Order article via Infotrieve]
23. Galis ZS, Kranzhofer R, Fenton JW, et al. Thrombin promotes activation of matrix metalloproteinase-2 produced by cultured vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 1997; 17: 483–489.
24. Mauriello A, Sangiorgi G, Palmieri G, et al. Hyperfibrinogenemia is associated with specific histocytological composition and complications of atherosclerotic carotid plaques in patients affected by transient ischemic attacks. Circulation. 2000; 101: 744–750.
25. Gupta R, Hansen J, Brunak S. Identifying intracellular O-(beta)-GlcNAc "yin-yang" switches in the available human proteome. Available at: http://www.cbs.dtu.dk/services/YinOYang. Accessed July 18, 2000.
26. Gurjar MV, Sharma RV, Bhalla RC. eNOS gene transfer inhibits smooth muscle cell migration and MMP-2 and MMP-9 activity. Arterioscler Thromb Vasc Biol. 1999; 19: 2871–2877.
27. Montagnani M, Golovchenko I, Kim I, et al. Inhibition of phosphatidylinositol 3-kinase enhances mitogenic actions of insulin in endothelial cells. J Biol Chem. 2001; 277: 1794–1799.[Medline] [Order article via Infotrieve]
28. Hu RM, Levin ER, Pedram A, et al. Insulin stimulates production and secretion of endothelin from bovine endothelial cells. Diabetes. 1993; 42: 351–358.[Abstract]
29. Oliver FJ, de la Rubia G, Feener EP, et al. Stimulation of endothelin-1 gene expression by insulin in endothelial cells. J Biol Chem. 1991; 266: 23251–23256.
30. Reusch HP, Zimmermann S, Schaefer M, et al. Regulation of Raf by Akt controls growth and differentiation in vascular smooth muscle cells. J Biol Chem. 2001; 276: 33630–33637.
31. Gratton JP, Morales-Ruiz M, Kureishi Y, et al. Akt down-regulation of p38 signaling provides a novel mechanism of vascular endothelial growth factor-mediated cytoprotection in endothelial cells. J Biol Chem. 2001; 276: 30359–30365.
32. Du XL, Edelstein D, Dimmeler S, et al. Hyperglycemia inhibits endothelial nitric oxide synthase activity by posttranslational modification at the Akt site. J Clin Invest. 2001; 108: 1341–1348.[CrossRef][Medline] [Order article via Infotrieve]
33. Meininger CJ, Kelly KA, Li H, et al. Glucosamine inhibits inducible nitric oxide synthesis. Biochem Biophys Res Commun. 2000; 279: 234–239.[CrossRef][Medline] [Order article via Infotrieve]
34. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature. 2001; 414: 813–820.[CrossRef][Medline] [Order article via Infotrieve]
35. Monauni T, Zenti MG, Cretti A, et al. Effects of glucosamine infusion on insulin secretion and insulin action in humans. Diabetes. 2000; 49: 926–935.[Abstract]
This article has been cited by other articles:
 |
|
 |
|
  A. G. Rajapakse, X.-F. Ming, J. M. Carvas, and Z. Yang The hexosamine biosynthesis inhibitor azaserine prevents endothelial inflammation and dysfunction under hyperglycemic condition through antioxidant effects Am J Physiol Heart Circ Physiol, March 1, 2009; 296(3): H815 - H822. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Arita, Y. Hata, S. Nakao, T. Kita, M. Miura, S. Kawahara, S. Zandi, L. Almulki, F. Tayyari, H. Shimokawa, et al. Rho Kinase Inhibition by Fasudil Ameliorates Diabetes-Induced Microvascular Damage Diabetes, January 1, 2009; 58(1): 215 - 226. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Laczy, B. G. Hill, K. Wang, A. J. Paterson, C. R. White, D. Xing, Y.-F. Chen, V. Darley-Usmar, S. Oparil, and J. C. Chatham Protein O-GlcNAcylation: a new signaling paradigm for the cardiovascular system Am J Physiol Heart Circ Physiol, January 1, 2009; 296(1): H13 - H28. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Fleming Double Tribble: Two TRIB3 Variants, Insulin, Akt, and eNOS Arterioscler. Thromb. Vasc. Biol., July 1, 2008; 28(7): 1216 - 1218. [Full Text] [PDF]
|
|
|
|
 |
|
 R. J. Copeland, J. W. Bullen, and G. W. Hart Cross-talk between GlcNAcylation and phosphorylation: roles in insulin resistance and glucose toxicity Am J Physiol Endocrinol Metab, July 1, 2008; 295(1): E17 - E28. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Spinetti, N. Kraenkel, C. Emanueli, and P. Madeddu Diabetes and vessel wall remodelling: from mechanistic insights to regenerative therapies Cardiovasc Res, May 1, 2008; 78(2): 265 - 273. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Luo, Y. Soesanto, and D. A. McClain Protein Modification by O-Linked GlcNAc Reduces Angiogenesis by Inhibiting Akt Activity in Endothelial Cells Arterioscler. Thromb. Vasc. Biol., April 1, 2008; 28(4): 651 - 657. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Muniyappa, M. Montagnani, K. K. Koh, and M. J. Quon Cardiovascular Actions of Insulin Endocr. Rev., August 1, 2007; 28(5): 463 - 491. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. M Hartge, T. Unger, and U. Kintscher The endothelium and vascular inflammation in diabetes Diabetes and Vascular Disease Research, June 1, 2007; 4(2): 84 - 88. [Abstract] [PDF]
|
|
|
|
|
|
N. Fulop, Z. Zhang, R. B. Marchase, and J. C. Chatham Glucosamine cardioprotection in perfused rat hearts associated with increased O-linked N-acetylglucosamine protein modification and altered p38 activation Am J Physiol Heart Circ Physiol, May 1, 2007; 292(5): H2227 - H2236. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Fulop, R. B. Marchase, and J. C. Chatham Role of protein O-linked N-acetyl-glucosamine in mediating cell function and survival in the cardiovascular system Cardiovasc Res, January 15, 2007; 73(2): 288 - 297. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Muniyappa, R. J. Karne, G. Hall, S. K. Crandon, J. A. Bronstein, M. R. Ver, G. L. Hortin, and M. J. Quon Oral Glucosamine for 6 Weeks at Standard Doses Does Not Cause or Worsen Insulin Resistance or Endothelial Dysfunction in Lean or Obese Subjects Diabetes, November 1, 2006; 55(11): 3142 - 3150. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Marchetti, R. Menghini, S. Rizza, A. Vivanti, T. Feccia, D. Lauro, A. Fukamizu, R. Lauro, and M. Federici Benfotiamine Counteracts Glucose Toxicity Effects on Endothelial Progenitor Cell Differentiation via Akt/FoxO Signaling. Diabetes, August 1, 2006; 55(8): 2231 - 2237. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Komers, W. E. Schutzer, J. F. Reed, J. N. Lindsley, T. T. Oyama, D. C. Buck, S. L. Mader, and S. Anderson Altered Endothelial Nitric Oxide Synthase Targeting and Conformation and Caveolin-1 Expression in the Diabetic Kidney Diabetes, June 1, 2006; 55(6): 1651 - 1659. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Martin, S. Rojas, A. Chamorro, C. Falcon, N. Bargallo, and A. M. Planas Why Does Acute Hyperglycemia Worsen the Outcome of Transient Focal Cerebral Ischemia?: Role of Corticosteroids, Inflammation, and Protein O-Glycosylation Stroke, May 1, 2006; 37(5): 1288 - 1295. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. R. Gosmanov, F. B. Stentz, and A. E. Kitabchi De novo emergence of insulin-stimulated glucose uptake in human aortic endothelial cells incubated with high glucose Am J Physiol Endocrinol Metab, March 1, 2006; 290(3): E516 - E522. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. E. Ball, M. N. Berkaw, and M. G. Buse Identification of the Major Site of O-Linked {beta}-N-Acetylglucosamine Modification in the C Terminus of Insulin Receptor Substrate-1 Mol. Cell. Proteomics, February 1, 2006; 5(2): 313 - 323. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. G. Buse Hexosamines, insulin resistance, and the complications of diabetes: current status Am J Physiol Endocrinol Metab, January 1, 2006; 290(1): E1 - E8. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Ma, H.-F. Zhang, L. Yu, Q.-J. Zhang, J. Li, J.-H. Huo, X. Li, W.-Y. Guo, H.-C. Wang, and F. Gao Vasculoprotective effect of insulin in the ischemic/reperfused canine heart: Role of Akt-stimulated NO production Cardiovasc Res, January 1, 2006; 69(1): 57 - 65. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Musicki, M. F. Kramer, R. E. Becker, and A. L. Burnett Inactivation of phosphorylated endothelial nitric oxide synthase (Ser-1177) by O-GlcNAc in diabetes-associated erectile dysfunction PNAS, August 16, 2005; 102(33): 11870 - 11875. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. B. Okon, A. W.Y. Chung, P. Rauniyar, E. Padilla, T. Tejerina, B. M. McManus, H. Luo, and C. van Breemen Compromised Arterial Function in Human Type 2 Diabetic Patients Diabetes, August 1, 2005; 54(8): 2415 - 2423. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Brownlee The Pathobiology of Diabetic Complications: A Unifying Mechanism Diabetes, June 1, 2005; 54(6): 1615 - 1625. [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Hu, D. Belke, J. Suarez, E. Swanson, R. Clark, M. Hoshijima, and W. H. Dillmann Adenovirus-Mediated Overexpression of O-GlcNAcase Improves Contractile Function in the Diabetic Heart Circ. Res., May 13, 2005; 96(9): 1006 - 1013. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Menghini, V. Marchetti, M. Cardellini, M. L. Hribal, A. Mauriello, D. Lauro, P. Sbraccia, R. Lauro, and M. Federici Phosphorylation of GATA2 by Akt Increases Adipose Tissue Differentiation and Reduces Adipose Tissue-Related Inflammation: A Novel Pathway Linking Obesity to Atherosclerosis Circulation, April 19, 2005; 111(15): 1946 - 1953. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. P. Kadoglou, S. S. Daskalopoulou, D. Perrea, and C. D. Liapis Matrix Metalloproteinases and Diabetic Vascular Complications Angiology, March 1, 2005; 56(2): 173 - 189. [Abstract] [PDF]
|
|
|
|
 |
|
 S. R. Kashyap, L. J. Roman, J. Lamont, B. S. S. Masters, M. Bajaj, S. Suraamornkul, R. Belfort, R. Berria, D. L. Kellogg Jr., Y. Liu, et al. Insulin Resistance Is Associated with Impaired Nitric Oxide Synthase Activity in Skeletal Muscle of Type 2 Diabetic Subjects J. Clin. Endocrinol. Metab., February 1, 2005; 90(2): 1100 - 1105. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Fulton, M. B. Harris, B. E. Kemp, R. C. Venema, M. B. Marrero, and D. W. Stepp Insulin resistance does not diminish eNOS expression, phosphorylation, or binding to HSP-90 Am J Physiol Heart Circ Physiol, December 1, 2004; 287(6): H2384 - H2393. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Bouche, S. Serdy, C. R. Kahn, and A. B. Goldfine The Cellular Fate of Glucose and Its Relevance in Type 2 Diabetes Endocr. Rev., October 1, 2004; 25(5): 807 - 830. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. H. Endemann and E. L. Schiffrin Endothelial Dysfunction J. Am. Soc. Nephrol., August 1, 2004; 15(8): 1983 - 1992. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. E. Zachara, N. O'Donnell, W. D. Cheung, J. J. Mercer, J. D. Marth, and G. W. Hart Dynamic O-GlcNAc Modification of Nucleocytoplasmic Proteins in Response to Stress: A SURVIVAL RESPONSE OF MAMMALIAN CELLS J. Biol. Chem., July 16, 2004; 279(29): 30133 - 30142. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. C. Schulze, J. Yoshioka, T. Takahashi, Z. He, G. L. King, and R. T. Lee Hyperglycemia Promotes Oxidative Stress through Inhibition of Thioredoxin Function by Thioredoxin-interacting Protein J. Biol. Chem., July 16, 2004; 279(29): 30369 - 30374. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Andreozzi, C. D'Alessandris, M. Federici, E. Laratta, S. Del Guerra, S. Del Prato, P. Marchetti, R. Lauro, F. Perticone, and G. Sesti Activation of the Hexosamine Pathway Leads to Phosphorylation of Insulin Receptor Substrate-1 on Ser307 and Ser612 and Impairs the Phosphatidylinositol 3-Kinase/Akt/Mammalian Target of Rapamycin Insulin Biosynthetic Pathway in RIN Pancreatic {beta}-Cells Endocrinology, June 1, 2004; 145(6): 2845 - 2857. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. I. Chisalita and H. J. Arnqvist Insulin-like growth factor I receptors are more abundant than insulin receptors in human micro- and macrovascular endothelial cells Am J Physiol Endocrinol Metab, June 1, 2004; 286(6): E896 - E901. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Parker, R. Taylor, D. Jones, and D. McClain Hyperglycemia and Inhibition of Glycogen Synthase in Streptozotocin-treated Mice: ROLE OF O-LINKED N-ACETYLGLUCOSAMINE J. Biol. Chem., May 14, 2004; 279(20): 20636 - 20642. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Andreozzi, E. Laratta, A. Sciacqua, F. Perticone, and G. Sesti Angiotensin II Impairs the Insulin Signaling Pathway Promoting Production of Nitric Oxide by Inducing Phosphorylation of Insulin Receptor Substrate-1 on Ser312 and Ser616 in Human Umbilical Vein Endothelial Cells Circ. Res., May 14, 2004; 94(9): 1211 - 1218. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Federici, A. Pandolfi, E. A. De Filippis, G. Pellegrini, R. Menghini, D. Lauro, M. Cardellini, M. Romano, G. Sesti, R. Lauro, et al. G972R IRS-1 Variant Impairs Insulin Regulation of Endothelial Nitric Oxide Synthase in Cultured Human Endothelial Cells Circulation, January 27, 2004; 109(3): 399 - 405. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. A. Whelan and G. W. Hart Proteomic Approaches to Analyze the Dynamic Relationships Between Nucleocytoplasmic Protein Glycosylation and Phosphorylation Circ. Res., November 28, 2003; 93(11): 1047 - 1058. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J. Vocadlo, H. C. Hang, E.-J. Kim, J. A. Hanover, and C. R. Bertozzi A chemical approach for identifying O-GlcNAc-modified proteins in cells PNAS, August 5, 2003; 100(16): 9116 - 9121. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||